CryoMass Technologies develops and licenses proprietary equipment that separates trichomes — the resin glands containing cannabinoids and terpenes — from harvested cannabis and hemp. CryoMass's core product is the CryoSift Separator, a machine that uses liquid nitrogen to make plant biomass brittle, then knocks off and collects intact trichomes. CryoMass argues that its cryogenic method better preserves trichome structure and potency compared to traditional separation methods like dry sift, ice water hash, or solvent-based extraction. CryoMass's patent portfolio, covering its cryogenic separation process across the U.S., Canada, and China, is its primary competitive moat. CryoMass targets large-scale cannabis and hemp cultivators and processors, selling or leasing the CryoSift Separator and licensing the underlying patented process. Revenue comes from upfront license fees, monthly royalties tied to a percentage of licensee revenues, and equipment sales or rentals. At scale, earnings would be driven by the number of units deployed and the volume of biomass processed by licensees. CryoMass is early-stage, with one active commercial unit installed as of the most recent reporting period. The company's growth strategy focuses on deploying more units across U.S. states and Canada, supported by a co-investment financing arrangement under which an investor affiliate can purchase units for deployment under lease arrangements, with processing fee revenue split equally between CryoMass and the investor.